APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anemia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchAnemia Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Anemia Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Anemia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anemia Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anemia Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Anemia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anemia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anemia Drugs include Eli Lilly, GlaxoSmithKline, Bayer AG, Regen Biopharma, Pieris Pharmaceuticals, Onconova Therapeutics, Mast Therapeutics, GlycoMimetics and Global Blood Therapeutics (GBT), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anemia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anemia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anemia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anemia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anemia Drugs Segment by Company

Eli Lilly

GlaxoSmithKline

Bayer AG

Regen Biopharma

Pieris Pharmaceuticals

Onconova Therapeutics

Mast Therapeutics

GlycoMimetics

Global Blood Therapeutics (GBT)

Fibrogen

Celgene Corporation

Bluebird Bio

Akebia Therapeutics

Acceleron Pharma

Anemia Drugs Segment by Type

Oral

Injection

Anemia Drugs Segment by Application

Aplastic Anemia

Iron Deficiency Anemia

Chronic Kidney Disease related Anemia

Sickle Cell Anemia

Anemia Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anemia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anemia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anemia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anemia Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anemia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anemia Drugs Industry Trends Table 2. Anemia Drugs Industry Drivers Table 3. Anemia Drugs Industry Opportunities and Challenges Table 4. Anemia Drugs Industry Restraints Table 5. Global Anemia Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anemia Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anemia Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anemia Drugs Sales Market Share by Manufacturers Table 9. Global Anemia Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anemia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anemia Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anemia Drugs Manufacturers, Product Type & Application Table 13. Global Anemia Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anemia Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Injection Table 18. Global Anemia Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Anemia Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Anemia Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Anemia Drugs Sales Market Share by Type (2021-2026) Table 22. Global Anemia Drugs Sales Market Share by Type (2027-2032) Table 23. Global Anemia Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Anemia Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Anemia Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Anemia Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Anemia Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Aplastic Anemia Table 29. Major Manufacturers of Iron Deficiency Anemia Table 30. Major Manufacturers of Chronic Kidney Disease related Anemia Table 31. Major Manufacturers of Sickle Cell Anemia Table 32. Global Anemia Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anemia Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Anemia Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Anemia Drugs Sales Market Share by Application (2021-2026) Table 36. Global Anemia Drugs Sales Market Share by Application (2027-2032) Table 37. Global Anemia Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Anemia Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Anemia Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Anemia Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Anemia Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Anemia Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anemia Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Anemia Drugs Sales Market Share by Region (2021-2026) Table 45. Global Anemia Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Anemia Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Anemia Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Anemia Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Anemia Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Anemia Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Anemia Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Anemia Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Anemia Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Anemia Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Anemia Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Anemia Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Anemia Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Anemia Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Anemia Drugs Revenue Market Share by Region (2027-2032) Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eli Lilly Anemia Drugs Product Portfolio Table 68. Eli Lilly Recent Development Table 69. GlaxoSmithKline Company Information Table 70. GlaxoSmithKline Business Overview Table 71. GlaxoSmithKline Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GlaxoSmithKline Anemia Drugs Product Portfolio Table 73. GlaxoSmithKline Recent Development Table 74. Bayer AG Company Information Table 75. Bayer AG Business Overview Table 76. Bayer AG Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer AG Anemia Drugs Product Portfolio Table 78. Bayer AG Recent Development Table 79. Regen Biopharma Company Information Table 80. Regen Biopharma Business Overview Table 81. Regen Biopharma Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Regen Biopharma Anemia Drugs Product Portfolio Table 83. Regen Biopharma Recent Development Table 84. Pieris Pharmaceuticals Company Information Table 85. Pieris Pharmaceuticals Business Overview Table 86. Pieris Pharmaceuticals Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pieris Pharmaceuticals Anemia Drugs Product Portfolio Table 88. Pieris Pharmaceuticals Recent Development Table 89. Onconova Therapeutics Company Information Table 90. Onconova Therapeutics Business Overview Table 91. Onconova Therapeutics Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Onconova Therapeutics Anemia Drugs Product Portfolio Table 93. Onconova Therapeutics Recent Development Table 94. Mast Therapeutics Company Information Table 95. Mast Therapeutics Business Overview Table 96. Mast Therapeutics Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Mast Therapeutics Anemia Drugs Product Portfolio Table 98. Mast Therapeutics Recent Development Table 99. GlycoMimetics Company Information Table 100. GlycoMimetics Business Overview Table 101. GlycoMimetics Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. GlycoMimetics Anemia Drugs Product Portfolio Table 103. GlycoMimetics Recent Development Table 104. Global Blood Therapeutics (GBT) Company Information Table 105. Global Blood Therapeutics (GBT) Business Overview Table 106. Global Blood Therapeutics (GBT) Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio Table 108. Global Blood Therapeutics (GBT) Recent Development Table 109. Fibrogen Company Information Table 110. Fibrogen Business Overview Table 111. Fibrogen Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Fibrogen Anemia Drugs Product Portfolio Table 113. Fibrogen Recent Development Table 114. Celgene Corporation Company Information Table 115. Celgene Corporation Business Overview Table 116. Celgene Corporation Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Celgene Corporation Anemia Drugs Product Portfolio Table 118. Celgene Corporation Recent Development Table 119. Bluebird Bio Company Information Table 120. Bluebird Bio Business Overview Table 121. Bluebird Bio Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Bluebird Bio Anemia Drugs Product Portfolio Table 123. Bluebird Bio Recent Development Table 124. Akebia Therapeutics Company Information Table 125. Akebia Therapeutics Business Overview Table 126. Akebia Therapeutics Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Akebia Therapeutics Anemia Drugs Product Portfolio Table 128. Akebia Therapeutics Recent Development Table 129. Acceleron Pharma Company Information Table 130. Acceleron Pharma Business Overview Table 131. Acceleron Pharma Anemia Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Acceleron Pharma Anemia Drugs Product Portfolio Table 133. Acceleron Pharma Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Anemia Drugs Distributors List Table 137. Anemia Drugs Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Anemia Drugs Product Image Figure 2. Global Anemia Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anemia Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anemia Drugs Sales (2021-2032) & (K Units) Figure 5. Global Anemia Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anemia Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Injection Image Figure 10. Global Anemia Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Anemia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anemia Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Anemia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Anemia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anemia Drugs Revenue Market Share by Type (2021-2032) Figure 16. Aplastic Anemia Image Figure 17. Iron Deficiency Anemia Image Figure 18. Chronic Kidney Disease related Anemia Image Figure 19. Sickle Cell Anemia Image Figure 20. Global Anemia Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anemia Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anemia Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Anemia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Anemia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Anemia Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Anemia Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Anemia Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Anemia Drugs Sales Market Share by Country (2021-2032) Figure 40. China Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Anemia Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Anemia Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Anemia Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Anemia Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Anemia Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Anemia Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Anemia Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Anemia Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Anemia Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Anemia Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Aplastic Anemia
  • Iron Deficiency Anemia
  • Chronic Kidney Disease related Anemia
  • Sickle Cell Anemia
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Bayer AG
  • Regen Biopharma
  • Pieris Pharmaceuticals
  • Onconova Therapeutics
  • Mast Therapeutics
  • GlycoMimetics
  • Global Blood Therapeutics (GBT)
  • Fibrogen
  • Celgene Corporation
  • Bluebird Bio
  • Akebia Therapeutics
  • Acceleron Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anemia Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anemia Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anemia Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anemia Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anemia Drugs Market Dynamics
  1. 2.1 Anemia Drugs Industry Trends
  2. 2.2 Anemia Drugs Industry Drivers
  3. 2.3 Anemia Drugs Industry Opportunities and Challenges
  4. 2.4 Anemia Drugs Industry Restraints
3 Anemia Drugs Market by Manufacturers
  1. 3.1 Global Anemia Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anemia Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anemia Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anemia Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anemia Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anemia Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Anemia Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anemia Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anemia Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anemia Drugs Tier 1, Tier 2, and Tier 3
4 Anemia Drugs Market by Type
  1. 4.1 Anemia Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Anemia Drugs Sales by Type
  5. 4.2.1 Global Anemia Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anemia Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Anemia Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anemia Drugs Revenue by Type
  9. 4.3.1 Global Anemia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anemia Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Anemia Drugs Revenue Market Share by Type (2021-2032)
5 Anemia Drugs Market by Application
  1. 5.1 Anemia Drugs Application Introduction
  2. 5.1.1 Aplastic Anemia
  3. 5.1.2 Iron Deficiency Anemia
  4. 5.1.3 Chronic Kidney Disease related Anemia
  5. 5.1.4 Sickle Cell Anemia
  6. 5.2 Global Anemia Drugs Sales by Application
  7. 5.2.1 Global Anemia Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anemia Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Anemia Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Anemia Drugs Revenue by Application
  11. 5.3.1 Global Anemia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anemia Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Anemia Drugs Revenue Market Share by Application (2021-2032)
6 Global Anemia Drugs Sales by Region
  1. 6.1 Global Anemia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anemia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anemia Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Anemia Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anemia Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anemia Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anemia Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anemia Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anemia Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anemia Drugs Revenue by Region
  1. 7.1 Global Anemia Drugs Revenue by Region
  2. 7.1.1 Global Anemia Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anemia Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Anemia Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Anemia Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anemia Drugs Revenue (2021-2032)
  8. 7.2.2 North America Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anemia Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anemia Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anemia Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anemia Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Anemia Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Anemia Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Bayer AG
  14. 8.3.1 Bayer AG Company Information
  15. 8.3.2 Bayer AG Business Overview
  16. 8.3.3 Bayer AG Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG Anemia Drugs Product Portfolio
  18. 8.3.5 Bayer AG Recent Developments
  19. 8.4 Regen Biopharma
  20. 8.4.1 Regen Biopharma Company Information
  21. 8.4.2 Regen Biopharma Business Overview
  22. 8.4.3 Regen Biopharma Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regen Biopharma Anemia Drugs Product Portfolio
  24. 8.4.5 Regen Biopharma Recent Developments
  25. 8.5 Pieris Pharmaceuticals
  26. 8.5.1 Pieris Pharmaceuticals Company Information
  27. 8.5.2 Pieris Pharmaceuticals Business Overview
  28. 8.5.3 Pieris Pharmaceuticals Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pieris Pharmaceuticals Anemia Drugs Product Portfolio
  30. 8.5.5 Pieris Pharmaceuticals Recent Developments
  31. 8.6 Onconova Therapeutics
  32. 8.6.1 Onconova Therapeutics Company Information
  33. 8.6.2 Onconova Therapeutics Business Overview
  34. 8.6.3 Onconova Therapeutics Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Onconova Therapeutics Anemia Drugs Product Portfolio
  36. 8.6.5 Onconova Therapeutics Recent Developments
  37. 8.7 Mast Therapeutics
  38. 8.7.1 Mast Therapeutics Company Information
  39. 8.7.2 Mast Therapeutics Business Overview
  40. 8.7.3 Mast Therapeutics Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mast Therapeutics Anemia Drugs Product Portfolio
  42. 8.7.5 Mast Therapeutics Recent Developments
  43. 8.8 GlycoMimetics
  44. 8.8.1 GlycoMimetics Company Information
  45. 8.8.2 GlycoMimetics Business Overview
  46. 8.8.3 GlycoMimetics Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlycoMimetics Anemia Drugs Product Portfolio
  48. 8.8.5 GlycoMimetics Recent Developments
  49. 8.9 Global Blood Therapeutics (GBT)
  50. 8.9.1 Global Blood Therapeutics (GBT) Company Information
  51. 8.9.2 Global Blood Therapeutics (GBT) Business Overview
  52. 8.9.3 Global Blood Therapeutics (GBT) Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Global Blood Therapeutics (GBT) Anemia Drugs Product Portfolio
  54. 8.9.5 Global Blood Therapeutics (GBT) Recent Developments
  55. 8.10 Fibrogen
  56. 8.10.1 Fibrogen Company Information
  57. 8.10.2 Fibrogen Business Overview
  58. 8.10.3 Fibrogen Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fibrogen Anemia Drugs Product Portfolio
  60. 8.10.5 Fibrogen Recent Developments
  61. 8.11 Celgene Corporation
  62. 8.11.1 Celgene Corporation Company Information
  63. 8.11.2 Celgene Corporation Business Overview
  64. 8.11.3 Celgene Corporation Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Celgene Corporation Anemia Drugs Product Portfolio
  66. 8.11.5 Celgene Corporation Recent Developments
  67. 8.12 Bluebird Bio
  68. 8.12.1 Bluebird Bio Company Information
  69. 8.12.2 Bluebird Bio Business Overview
  70. 8.12.3 Bluebird Bio Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bluebird Bio Anemia Drugs Product Portfolio
  72. 8.12.5 Bluebird Bio Recent Developments
  73. 8.13 Akebia Therapeutics
  74. 8.13.1 Akebia Therapeutics Company Information
  75. 8.13.2 Akebia Therapeutics Business Overview
  76. 8.13.3 Akebia Therapeutics Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Akebia Therapeutics Anemia Drugs Product Portfolio
  78. 8.13.5 Akebia Therapeutics Recent Developments
  79. 8.14 Acceleron Pharma
  80. 8.14.1 Acceleron Pharma Company Information
  81. 8.14.2 Acceleron Pharma Business Overview
  82. 8.14.3 Acceleron Pharma Anemia Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Acceleron Pharma Anemia Drugs Product Portfolio
  84. 8.14.5 Acceleron Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anemia Drugs Value Chain Analysis
  2. 9.1.1 Anemia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anemia Drugs Production Mode & Process
  6. 9.2 Anemia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anemia Drugs Distributors
  9. 9.2.3 Anemia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst